Apple v Masimo
Apple to halt some Apple Watch Sales in US
Apple is planning to stop selling some versions of the Apple Watch in the United States as soon as this week to get ahead of what could be one of the most momentous patent disputes in years.
Biden administration upholds Apple Watch ban
US president Joe Biden's administration on Tuesday opted not to veto a government tribunal's ruling to ban imports of Apple Watches.
Apple files emergency motion against Apple Watch ban
Apple filed an emergency motion with a U.S. appeals court to pause a ban on importing and selling some of its Apple Watch models.
U.S. Appeals Court temporarily stops Apple Watch Sales Ban
Apple will be able to sell the latest Apple Watches after an import ban was temporarily stopped by a U.S. appeals court on Wednesday.
Apple Resumes Watch Series 9 and Ultra 2 Sales in U.S.
Apple has started resuming sales of its Apple Watch Series 9 and Ultra 2 in the country.
Apple to Remove Blood-Oxygen Tool From Apple Watches
Apple is planning to remove its blood-oxygen feature from the Apple Watch Series 9 and Apple Watch Ultra 2, to circumvent a US ban of the devices.
Apple Watches Banned again in U.S.
From Jan. 18, Apple will again be banned from selling Apple Watch Series 9 and Ultra 2 devices in the US due to its ongoing patent infringement case with Masimo.
Apple iOS 18.6.1 restores blood oxygen monitoring in the United States
Apple has released iOS 18.6.1 for U.S. iPhones only, bringing a Blood Oxygen monitoring update.
Apple watchOS 11.6.1 restores blood oxygen monitoring in the United States
Apple has released watchOS 11.6.1 in tandem with iOS 18.6.1 bringing a Blood Oxygen monitoring update in the United States.
Masimo sues US Customs over Apple Watch Blood Oxygen feature
Masimo has filed a lawsuit against U.S. Customs and Border Protection (CBP) over the reactivation of the Apple Watch’s Blood Oxygen feature.
US Customs asks court to dismiss Masimo case
Masimo recently filed a lawsuit against U.S. Customs and Border Protection, accusing the agency of improperly allowing Apple to resume selling Apple Watches with the Blood Oxygen feature activated.
US Jury orders Apple to pay Masimo $634M in never ending patent fight
A federal jury in California has found that Apple infringed on a Masimo patent for its pulse oximetry technology and awarded Masimo $634 million in damages.
Apple Watch Blood Oxygen Workaround Doesn’t Infringe on Masimo Patents
U.S. International Trade Commission (ITC) judge has determined that Apple’s current methods of leveraging blood oxygen sensing on Apple Watch do not infringe on Masimo’s patents
Apple smartwatches could face an import ban after a U.S. judge ruled that the company infringed on one of Masimo’s pulse oximeter patents.
A U.S. administrative law judge ruled that by importing and selling some Apple Watches with light-based pulse oximetry functionality and components, Apple infringed on the medical device maker’s patent.
The United States International Trade Commission (USITC) will now deliberate on the possibility of implementing an import ban on these Apple Watches.
According to Masimo, in 2020, Apple first introduced a pulse oximeter sensor with the Apple Watch Series 6 and continues to integrate the technology in its current smartwatches.
“We are happy that the ALJ recognized Apple’s infringement of Masimo’s pulse oximetry technology and took this critical first step toward accountability,” said Joe Kiani, CEO of Masimo.
“Today’s decision should help restore fairness in the market. Apple has similarly infringed on other companies’ technologies, and we believe today’s ruling exposes Apple as a company that takes other companies’ innovations and repackages them.”
Masimo makes pulse oximeters for medical use, having revolutionized the industry with its Masimo SET pulse oximetry technology, proven to help reduce blindness in babies in the neonatal intensive care unit, save lives of post-surgical patients on opioids and COVID patients monitored remotely.
“We respectfully disagree with today’s decision, and look forward to a full review by the Commission,” Apple said in a statement.



